<author><surname>Aboujaoude</surname> <given-names>E</given-names> </author><author><surname>Barry</surname> <given-names>JJ</given-names> </author><author><surname>Gamel</surname> <given-names>N</given-names> </author><title>Memantine augmentation in treatment-resistant obsessive&#8211;compulsive disorder: an open-label trial</title><source>J Clin Psychopharmacol</source><year>2009</year><volume>29</volume><fpage>51</fpage><lpage>55</lpage>
<author><surname>Abramowitz</surname> <given-names>JS</given-names> </author><author><surname>Taylor</surname> <given-names>S</given-names> </author><author><surname>McKay</surname> <given-names>D</given-names> </author><title>Obsessive&#8211;compulsive disorder</title><source>Lancet</source><year>2009</year><volume>374</volume><fpage>491</fpage><lpage>499</lpage>
<author><surname>Amiel</surname> <given-names>JM</given-names> </author><author><surname>Mathew</surname> <given-names>SJ</given-names> </author><title>Glutamate and anxiety disorders</title><source>Curr Psychiatry Rep</source><year>2007</year><volume>9</volume><fpage>278</fpage><lpage>283</lpage>
<author><surname>Anthony</surname> <given-names>EW</given-names> </author><author><surname>Nevins</surname> <given-names>ME</given-names> </author><title>Anxiolytic-like effects of N-methyl-</title><source>Eur J Pharmacol</source><year>1993</year><volume>250</volume><fpage>317</fpage><lpage>324</lpage>
<author><surname>Boyce-Rustay</surname> <given-names>JM</given-names> </author><author><surname>Holmes</surname> <given-names>A</given-names> </author><title>Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice</title><source>Neuropsychopharmacology</source><year>2006</year><volume>31</volume><fpage>2405</fpage><lpage>2414</lpage>
<author><surname>Campeau</surname> <given-names>S</given-names> </author><author><surname>Miserendino</surname> <given-names>MJ</given-names> </author><author><surname>Davis</surname> <given-names>M</given-names> </author><title>Intra-amygdala infusion of the N-methyl-</title><source>Behav Neurosci</source><year>1992</year><volume>106</volume><fpage>569</fpage><lpage>574</lpage>
<author><surname>Coric</surname> <given-names>V</given-names> </author><author><surname>Taskiran</surname> <given-names>S</given-names> </author><author><surname>Pittenger</surname> <given-names>C</given-names> </author><author><surname>Wasylink</surname> <given-names>S</given-names> </author><author><surname>Mathalon</surname> <given-names>DH</given-names> </author><author><surname>Valentine</surname> <given-names>G</given-names> </author><author><surname>Saksa</surname> <given-names>J</given-names> </author><author><surname>Wu</surname> <given-names>YT</given-names> </author><author><surname>Gueorguieva</surname> <given-names>R</given-names> </author><author><surname>Sanacora</surname> <given-names>G</given-names> </author><author><surname>Malison</surname> <given-names>RT</given-names> </author><author><surname>Krystal</surname> <given-names>JH</given-names> </author><title>Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial</title><source>Biol Psychiatry</source><year>2005</year><volume>58</volume><fpage>424</fpage><lpage>428</lpage>
<author><surname>Dunn</surname> <given-names>RW</given-names> </author><author><surname>Corbett</surname> <given-names>R</given-names> </author><author><surname>Fielding</surname> <given-names>S</given-names> </author><title>Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze</title><source>Eur J Pharmacol</source><year>1989</year><volume>169</volume><fpage>1</fpage><lpage>10</lpage>
<author><surname>Emmett</surname> <given-names>MR</given-names> </author><author><surname>Mick</surname> <given-names>SJ</given-names> </author><author><surname>Cler</surname> <given-names>JA</given-names> </author><author><surname>Rao</surname> <given-names>TS</given-names> </author><author><surname>Iyengar</surname> <given-names>S</given-names> </author><author><surname>Wood</surname> <given-names>PL</given-names> </author><title>Actions of </title><source>Neuropharmacology</source><year>1991</year><volume>30</volume><fpage>1167</fpage><lpage>1171</lpage>
<author><surname>Fendt</surname> <given-names>M</given-names> </author><author><surname>Koch</surname> <given-names>M</given-names> </author><author><surname>Schnitzler</surname> <given-names>HU</given-names> </author><title>NMDA receptors in the pontine brainstem are necessary for fear potentiation of the startle response</title><source>Eur J Pharmacol</source><year>1996</year><volume>318</volume><fpage>1</fpage><lpage>6</lpage>
<author><surname>Feusner</surname> <given-names>JD</given-names> </author><author><surname>Kerwin</surname> <given-names>L</given-names> </author><author><surname>Saxena</surname> <given-names>S</given-names> </author><author><surname>Bystritsky</surname> <given-names>A</given-names> </author><title>Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial</title><source>Psychopharmacol Bull</source><year>2009</year><volume>42</volume><fpage>81</fpage><lpage>93</lpage>
<author><surname>Heresco-Levy</surname> <given-names>U</given-names> </author><author><surname>Kremer</surname> <given-names>I</given-names> </author><author><surname>Javitt</surname> <given-names>DC</given-names> </author><author><surname>Goichman</surname> <given-names>R</given-names> </author><author><surname>Reshef</surname> <given-names>A</given-names> </author><author><surname>Blanaru</surname> <given-names>M</given-names> </author><author><surname>Cohen</surname> <given-names>T</given-names> </author><title>Pilot-controlled trial of </title><source>Int J Neuropsychopharmacol</source><year>2002</year><volume>5</volume><fpage>301</fpage><lpage>307</lpage>
<author><surname>Ho</surname> <given-names>YJ</given-names> </author><author><surname>Hsu</surname> <given-names>LS</given-names> </author><author><surname>Wang</surname> <given-names>CF</given-names> </author><author><surname>Hsu</surname> <given-names>WY</given-names> </author><author><surname>Lai</surname> <given-names>TJ</given-names> </author><author><surname>Hsu</surname> <given-names>CC</given-names> </author><author><surname>Tsai</surname> <given-names>YF</given-names> </author><title>Behavioral effects of </title><source>Brain Res</source><year>2005</year><volume>1043</volume><fpage>179</fpage><lpage>185</lpage>
<author><surname>Hood</surname> <given-names>WF</given-names> </author><author><surname>Compton</surname> <given-names>RP</given-names> </author><author><surname>Monahan</surname> <given-names>JB</given-names> </author><title /><source>Neurosci Lett</source><year>1989</year><volume>98</volume><fpage>91</fpage><lpage>95</lpage>
<author><surname>Johnson</surname> <given-names>JW</given-names> </author><author><surname>Ascher</surname> <given-names>P</given-names> </author><title>Glycine potentiates the NMDA response in cultured mouse brain neurons</title><source>Nature</source><year>1987</year><volume>325</volume><fpage>529</fpage><lpage>531</lpage>
<author><surname>Kalueff</surname> <given-names>A</given-names> </author><author><surname>Nutt</surname> <given-names>DJ</given-names> </author><title>Role of GABA in memory and anxiety</title><source>Depress Anxiety</source><year>1996</year><volume>4</volume><fpage>100</fpage><lpage>110</lpage>
<author><surname>Karcz-Kubicha</surname> <given-names>M</given-names> </author><author><surname>Jessa</surname> <given-names>M</given-names> </author><author><surname>Nazar</surname> <given-names>M</given-names> </author><author><surname>Pla&#378;nik</surname> <given-names>A</given-names> </author><author><surname>Hartmann</surname> <given-names>S</given-names> </author><author><surname>Parsons</surname> <given-names>CG</given-names> </author><author><surname>Danysz</surname> <given-names>W</given-names> </author><title>Anxiolytic activity of glycine-B antagonists and partial agonists&#8211;no relation to intrinsic activity in the patch clamp</title><source>Neuropharmacology</source><year>1997</year><volume>36</volume><fpage>1355</fpage><lpage>1367</lpage>
<author><surname>Kessler</surname> <given-names>M</given-names> </author><author><surname>Terramani</surname> <given-names>T</given-names> </author><author><surname>Lynch</surname> <given-names>G</given-names> </author><author><surname>Baudry</surname> <given-names>M</given-names> </author><title>A glycine site associated with N-methyl-</title><source>J Neurochem</source><year>1989</year><volume>52</volume><fpage>1319</fpage><lpage>1328</lpage>
<author><surname>Kew</surname> <given-names>JN</given-names> </author><author><surname>Kemp</surname> <given-names>JA</given-names> </author><title>Ionotropic and metabotropic glutamate receptor structure and pharmacology</title><source>Psychopharmacology (Berl)</source><year>2005</year><volume>179</volume><fpage>4</fpage><lpage>29</lpage>
<author><surname>Kleckner</surname> <given-names>NW</given-names> </author><author><surname>Dingledine</surname> <given-names>R</given-names> </author><title>Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes</title><source>Science</source><year>1988</year><volume>241</volume><fpage>835</fpage><lpage>837</lpage>
<author><surname>Kleckner</surname> <given-names>NW</given-names> </author><author><surname>Dingledine</surname> <given-names>R</given-names> </author><title>Selectivity of quinoxalines and kynurenines as antagonists of the glycine site on N-methyl-</title><source>Mol Pharmacol</source><year>1989</year><volume>36</volume><fpage>430</fpage><lpage>436</lpage>
<author><surname>K&#322;odzi&#324;ska</surname> <given-names>A</given-names> </author><author><surname>Chojnacka-W&#243;jcik</surname> <given-names>E</given-names> </author><title>Anticonflict effect of the glycineB receptor partial agonist, </title><source>Psychopharmacology (Berl)</source><year>2000</year><volume>152</volume><fpage>224</fpage><lpage>228</lpage>
<author><surname>Kotli&#324;ska</surname> <given-names>J</given-names> </author><author><surname>Liljequist</surname> <given-names>S</given-names> </author><title>A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701, 324</title><source>Psychopharmacology (Berl)</source><year>1998</year><volume>135</volume><fpage>175</fpage><lpage>181</lpage>
<author><surname>Krystal</surname> <given-names>JH</given-names> </author><author><surname>D&#8217;Souza</surname> <given-names>DC</given-names> </author><author><surname>Petrakis</surname> <given-names>IL</given-names> </author><author><surname>Belger</surname> <given-names>A</given-names> </author><author><surname>Berman</surname> <given-names>RM</given-names> </author><author><surname>Charney</surname> <given-names>DS</given-names> </author><author><surname>Abi-Saab</surname> <given-names>W</given-names> </author><author><surname>Madonick</surname> <given-names>S</given-names> </author><title>NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders</title><source>Harv Rev Psychiatry</source><year>1999</year><volume>7</volume><fpage>125</fpage><lpage>143</lpage>
<author><surname>Lipman</surname> <given-names>JJ</given-names> </author><author><surname>Spencer</surname> <given-names>PS</given-names> </author><title>Rapid intracerebroventricular injection assisted by an automatic syringe</title><source>J Pharmacol Methods</source><year>1980</year><volume>4</volume><fpage>327</fpage><lpage>333</lpage>
<author><surname>Lister</surname> <given-names>RG</given-names> </author><title>The use of a plus-maze to measure anxiety in the mouse</title><source>Psychopharmacology (Berl)</source><year>1987</year><volume>92</volume><fpage>180</fpage><lpage>185</lpage>
<author><surname>Lydiard</surname> <given-names>RB</given-names> </author><title>The role of GABA in anxiety disorders</title><source>J Clin Psychiatry</source><year>2003</year><volume>64</volume><issue>Suppl 3</issue><fpage>21</fpage><lpage>27</lpage>
<author><surname>Mathew</surname> <given-names>SJ</given-names> </author><author><surname>Amiel</surname> <given-names>JM</given-names> </author><author><surname>Coplan</surname> <given-names>JD</given-names> </author><author><surname>Fitterling</surname> <given-names>HA</given-names> </author><author><surname>Sackeim</surname> <given-names>HA</given-names> </author><author><surname>Gorman</surname> <given-names>JM</given-names> </author><title>Open-label trial of riluzole in generalized anxiety disorder</title><source>Am J Psychiatry</source><year>2005</year><volume>162</volume><fpage>2379</fpage><lpage>2381</lpage>
<author><surname>Nemeroff</surname> <given-names>CB</given-names> </author><title>The role of GABA in the pathophysiology and treatment of anxiety disorders</title><source>Psychopharmacol Bull</source><year>2003</year><volume>37</volume><fpage>133</fpage><lpage>146</lpage>
<author><surname>Nutt</surname> <given-names>DJ</given-names> </author><author><surname>Malizia</surname> <given-names>AL</given-names> </author><title>New insights into the role of the GABAA-benzodiazepine receptor in psychiatric disorder</title><source>Br J Psychiatry</source><year>2001</year><volume>179</volume><fpage>390</fpage><lpage>396</lpage>
<author><surname>Parsons</surname> <given-names>CG</given-names> </author><author><surname>Danysz</surname> <given-names>W</given-names> </author><author><surname>Quack</surname> <given-names>G</given-names> </author><title>Glutamate in CNS disorders as a target for drug development: an update</title><source>Drug News Perspect</source><year>1998</year><volume>11</volume><fpage>523</fpage><lpage>569</lpage>
<author><surname>Pellow</surname> <given-names>S</given-names> </author><title>Anxiolytic and anxiogenic drug effects in a novel test of anxiety: are exploratory models of anxiety in rodents valid?</title><source>Methods Find Exp Clin Pharmacol</source><year>1986</year><volume>8</volume><fpage>557</fpage><lpage>565</lpage>
<author><surname>Pellow</surname> <given-names>S</given-names> </author><author><surname>Chopin</surname> <given-names>P</given-names> </author><author><surname>File</surname> <given-names>SE</given-names> </author><author><surname>Briley</surname> <given-names>M</given-names> </author><title>Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat</title><source>J Neurosci Methods</source><year>1985</year><volume>14</volume><fpage>149</fpage><lpage>167</lpage>
<author><surname>P&#322;a&#378;nik</surname> <given-names>A</given-names> </author><author><surname>Pa&#322;ejko</surname> <given-names>W</given-names> </author><author><surname>Nazar</surname> <given-names>M</given-names> </author><author><surname>Jessa</surname> <given-names>M</given-names> </author><title>Effects of antagonists at the NMDA receptor complex in two models of anxiety</title><source>Eur Neuropsychopharmacol</source><year>1994</year><volume>4</volume><fpage>503</fpage><lpage>512</lpage>
<author><surname>Poleszak</surname> <given-names>E</given-names> </author><author><surname>Szewczyk</surname> <given-names>B</given-names> </author><author><surname>K&#281;dzierska</surname> <given-names>E</given-names> </author><author><surname>Wla&#378;</surname> <given-names>P</given-names> </author><author><surname>Pilc</surname> <given-names>A</given-names> </author><author><surname>Nowak</surname> <given-names>G</given-names> </author><title>Antidepressant- and anxiolytic-like activity of magnesium in mice</title><source>Pharmacol Biochem Behav</source><year>2004</year><volume>78</volume><fpage>7</fpage><lpage>12</lpage>
<author><surname>Poleszak</surname> <given-names>E</given-names> </author><author><surname>Wla&#378;</surname> <given-names>P</given-names> </author><author><surname>Wr&#243;bel</surname> <given-names>A</given-names> </author><author><surname>Fidecka</surname> <given-names>S</given-names> </author><author><surname>Nowak</surname> <given-names>G</given-names> </author><title>NMDA/glutamate mechanism of magnesium-induced anxiolytic-like behavior in mice</title><source>Pharmacol Rep</source><year>2008</year><volume>60</volume><fpage>655</fpage><lpage>663</lpage>
<author><surname>Przegali&#324;ski</surname> <given-names>E</given-names> </author><author><surname>Tatarczy&#324;ska</surname> <given-names>E</given-names> </author><author><surname>Chojnacka-W&#243;jcik</surname> <given-names>E</given-names> </author><title>Anxiolytic- and antidepressant-like effects of an antagonist at glycineB receptors</title><source>Pol J Pharmacol</source><year>1998</year><volume>50</volume><fpage>349</fpage><lpage>354</lpage>
<author><surname>Przegali&#324;ski</surname> <given-names>E</given-names> </author><author><surname>Tatarczy&#324;ska</surname> <given-names>E</given-names> </author><author><surname>Chojnacka-W&#243;jcik</surname> <given-names>E</given-names> </author><title>The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats</title><source>Neuropharmacology</source><year>2000</year><volume>39</volume><fpage>1858</fpage><lpage>1864</lpage>
<author><surname>Ressler</surname> <given-names>KJ</given-names> </author><author><surname>Rothbaum</surname> <given-names>BO</given-names> </author><author><surname>Tannenbaum</surname> <given-names>L</given-names> </author><author><surname>Anderson</surname> <given-names>P</given-names> </author><author><surname>Graap</surname> <given-names>K</given-names> </author><author><surname>Zimand</surname> <given-names>E</given-names> </author><author><surname>Hodges</surname> <given-names>L</given-names> </author><author><surname>Davis</surname> <given-names>M</given-names> </author><title>Cognitive enhancers as adjuncts to psychotherapy: use of </title><source>Arch Gen Psychiatry</source><year>2004</year><volume>61</volume><fpage>1136</fpage><lpage>1144</lpage>
<author><surname>Sharma</surname> <given-names>AC</given-names> </author><author><surname>Kulkarni</surname> <given-names>SK</given-names> </author><title>Evidence for benzodiazepine receptor interaction with MK 801 in anxiety related behaviour in rats</title><source>Indian J Exp Biol</source><year>1993</year><volume>31</volume><fpage>191</fpage><lpage>193</lpage>
<author><surname>Sieghart</surname> <given-names>W</given-names> </author><title>Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes</title><source>Pharmacol Rev</source><year>1995</year><volume>47</volume><fpage>181</fpage><lpage>234</lpage>
<author><surname>Sieghart</surname> <given-names>W</given-names> </author><author><surname>Fuchs</surname> <given-names>K</given-names> </author><author><surname>Tretter</surname> <given-names>V</given-names> </author><author><surname>Ebert</surname> <given-names>V</given-names> </author><author><surname>Jechlinger</surname> <given-names>M</given-names> </author><author><surname>Hoger</surname> <given-names>H</given-names> </author><author><surname>Adamiker</surname> <given-names>D</given-names> </author><title>Structure and subunit composition of GABAA receptors</title><source>Neurochem Int</source><year>1999</year><volume>34</volume><fpage>379</fpage><lpage>385</lpage>
<author><surname>Stahl</surname> <given-names>SM</given-names> </author><title>Don&#8217;t ask, don&#8217;t tell, but benzodiazepines are still the leading treatments for anxiety disorder</title><source>J Clin Psychiatry</source><year>2002</year><volume>63</volume><fpage>756</fpage><lpage>757</lpage>
<author><surname>Tricklebank</surname> <given-names>MD</given-names> </author><author><surname>Singh</surname> <given-names>L</given-names> </author><author><surname>Oles</surname> <given-names>RJ</given-names> </author><author><surname>Preston</surname> <given-names>C</given-names> </author><author><surname>Iversen</surname> <given-names>SD</given-names> </author><title>The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor</title><source>Eur J Pharmacol</source><year>1989</year><volume>167</volume><fpage>127</fpage><lpage>135</lpage>
<author><surname>Trullas</surname> <given-names>R</given-names> </author><author><surname>Jackson</surname> <given-names>B</given-names> </author><author><surname>Skolnick</surname> <given-names>P</given-names> </author><title>Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors</title><source>Pharmacol Biochem Behav</source><year>1989</year><volume>34</volume><fpage>313</fpage><lpage>316</lpage>
<author><surname>Trullas</surname> <given-names>R</given-names> </author><author><surname>Folio</surname> <given-names>T</given-names> </author><author><surname>Young</surname> <given-names>A</given-names> </author><author><surname>Miller</surname> <given-names>R</given-names> </author><author><surname>Boje</surname> <given-names>K</given-names> </author><author><surname>Skolnick</surname> <given-names>P</given-names> </author><title /><source>Eur J Pharmacol</source><year>1991</year><volume>203</volume><fpage>379</fpage><lpage>385</lpage>
<author><surname>Uhlenhuth</surname> <given-names>EH</given-names> </author><author><surname>Balter</surname> <given-names>MB</given-names> </author><author><surname>Ban</surname> <given-names>TA</given-names> </author><author><surname>Yang</surname> <given-names>K</given-names> </author><title>International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders</title><source>J Clin Psychopharmacol</source><year>1999</year><volume>19</volume><fpage>23S</fpage><lpage>29S</lpage>
<author><surname>Watson</surname> <given-names>GB</given-names> </author><author><surname>Bolanowski</surname> <given-names>MA</given-names> </author><author><surname>Baganoff</surname> <given-names>MP</given-names> </author><author><surname>Deppeler</surname> <given-names>CL</given-names> </author><author><surname>Lanthorn</surname> <given-names>TH</given-names> </author><title /><source>Brain Res</source><year>1990</year><volume>510</volume><fpage>158</fpage><lpage>160</lpage>
<author><surname>Willetts</surname> <given-names>J</given-names> </author><author><surname>Balster</surname> <given-names>RL</given-names> </author><author><surname>Leander</surname> <given-names>JD</given-names> </author><title>The behavioral pharmacology of NMDA receptor antagonists</title><source>Trends Pharmacol Sci</source><year>1990</year><volume>11</volume><fpage>423</fpage><lpage>428</lpage>
<author><surname>Wood</surname> <given-names>PL</given-names> </author><author><surname>Emmett</surname> <given-names>MR</given-names> </author><author><surname>Rao</surname> <given-names>TS</given-names> </author><author><surname>Mick</surname> <given-names>S</given-names> </author><author><surname>Cler</surname> <given-names>J</given-names> </author><author><surname>Iyengar</surname> <given-names>S</given-names> </author><title>In vivo modulation of the N-methyl-</title><source>J Neurochem</source><year>1989</year><volume>53</volume><fpage>979</fpage><lpage>981</lpage>
<author><surname>Wood</surname> <given-names>PL</given-names> </author><author><surname>Hawkinson</surname> <given-names>JE</given-names> </author><author><surname>Goodnough</surname> <given-names>DB</given-names> </author><title>Formation of </title><source>J Neurochem</source><year>1996</year><volume>67</volume><fpage>1485</fpage><lpage>1490</lpage>